News for Prothena Corporation plc (PRTA)

Prothena Corporation plc (NASDAQ:PRTA) today announced that the Company has initiated an approximate 63% reduction in its workforce to substantially reduce its

Prothena Corporation plc (PRTA) announces a 63% workforce reduction to cut operating costs. The company revises its 2025 financial guidance, projecting

Roche to advance prasinezumab to Phase III trials for early-stage Parkinson's disease. Phase IIb PADOVA study suggests potential clinical benefits for p

The price target decrease followed the company's announcement on May 23 that its Phase 3 AFFIRM-AL clinical trial for Birtamimab in AL Amyloidosis patients had failed to meet the primary endpoint.

This rating update came after Prothena Corporation's (NASDAQ:PRTA) May 23 announcement that its Phase 3 AFFIRM-AL trial for birtamimab in amyloid light chain amyloidosis failed to meet the primary endpoint...

On May 27, Jefferies downgraded Prothena Corporation plc (NASDAQ:PRTA) to Hold from Buy and slashed the price target to $6 from $32. The considerable price target reduction followed the company’s announcement regarding the discontinuation of its Phase 3 AFFIRM-AL clinical trial for Birtamimab in AL Amyloidosis patients, as it could not meet the primary and […]

U.S. stock futures were higher this morning, with the Dow futures gaining more than 500 points on Tuesday. Shares of PDD Holdings Inc. PDD fell sharply in toda...

Prothena Corporation plc (NASDAQ:PRTA) released data from the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis on Friday. AL (amyloid light-chain) amyloidosis is a systemic disease where abnormal proteins, called amyloid fibrils, accumulate in various organs. It’s the most common type of systemic amyloidosis. The Phase 3 AFFIRM-AL trial enrolled 207 newly diagnosed patients. Birtamimab was given to the active arm every 28 days at a dose level of 24 mg/kg (ma

U.S. stock futures rose on Tuesday after closing lower for the week on Friday. Futures of benchmark indices were trading higher in premarket.

Prothena Corporation plc (NASDAQ:PRTA) today announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a...

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dys

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dys

Prothena Corporation is advancing Birtamimab for AL amyloidosis. Learn why PRTA stock is risky with uncertain upcoming data and past trial disappointments.

Prothena Corporation plc (NASDAQ:PRTA) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ETCompany ParticipantsMark Johnson - Vice President of...

NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Pro

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

Prothena stock soars despite study miss

U.S. stocks were higher, with the Dow Jones index gaining over 150 points on Thursday. Shares of Accenture plc ACN rose sharply in today's session after the co...